A Phase 3 interventional study of Trastuzumab in HER2-positive Carcinoma of Breast, sponsored by Celltrion. Completed at 98 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-03.
Sponsored by Celltrion · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will determine whether CT-P6 and Herceptin are equivalent in patients with early-stage breast cancer undergoing neoadjuvant chemotherapy. Our hypothesis is that the pathologic complete response rate will be equivalent in patients treated with neoadjuvant CT-P6 or Herceptin. Patients will receive 8 cycles of neoadjuvant systemic therapy and up to 10 cycles of therapy in the adjuvant setting.
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Trastuzumab
Drug: Trastuzumab
Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
Also known as: Herceptin
The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)
The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)
The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)
Overall Response Rate (ORR) From Local Review
The ORR was defined as the proportion of patients with a BOR of CR or PR as assessed by RECIST guideline Version 1.1 during the Nedadjuvant Period.
Time frame: After Neo-adjuvant therapy (up to 24 weeks)
Disease-free Survival
Patients who underwent breast surgery were included in the DFS analysis. Disease-free survival was defined as the interval between the date of breast surgery and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.
Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)
Progression-Free Survival
Progression-free survival was defined as the interval between randomization and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.
Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)
Overall Survival
Overall survival was defined as the interval between randomization and death from any cause.
Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)
The Number of Patients Who Had Progressive Disease or Recurrence
If recurrence or progression of disease occurred at any time during the study, the progressed tumor site was recorded in the "recurrence or progression of disease" eCRF page as local, regional, or distant, with diagnostic method and whether positive cytology or histology or not. The resulting recurrence or progression of disease information was summarized as secondary endpoint.
Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)
Maximum Serum Concentration After Administration (Cmax) in Each Cycle
Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.
Time frame: End of each treatment cycles, up to 24 weeks (during neoadjuvant period)
Trough Serum Concentration (Ctrough) in Each Cycle
Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.
Time frame: Pre-infusion of cycles 1 to 8 during neoadjuvant period
| Milestone | CT-P6 | Herceptin |
|---|---|---|
| Started | 278 | 284 |
| Completed | 264 | 267 |
| Not completed | 14 | 17 |
| Milestone | CT-P6 | Herceptin |
|---|---|---|
| Started | 260 | 268 |
| Completed | 248 | 255 |
| Not completed | 12 | 13 |
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
| percentage of responders | CT-P6 | Herceptin |
|---|---|---|
| The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS) | 46.77 (40.43 to 53.19) | 50.39 (44.10 to 56.68) |
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
| percentage of responders | CT-P6 | Herceptin |
|---|---|---|
| The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status | 4.84 (2.52 to 8.30) | 4.69 (2.45 to 8.04) |
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
| percentage of responders | CT-P6 | Herceptin |
|---|---|---|
| The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS | 39.92 (33.78 to 46.31) | 41.41 (35.31 to 47.71) |
The ORR was defined as the proportion of patients with a BOR of CR or PR as assessed by RECIST guideline Version 1.1 during the Nedadjuvant Period.
| percentage of responders | CT-P6 | Herceptin |
|---|---|---|
| Overall Response Rate (ORR) From Local Review | 84.27 (79.14 to 88.57) | 83.98 (78.91 to 88.26) |
Patients who underwent breast surgery were included in the DFS analysis. Disease-free survival was defined as the interval between the date of breast surgery and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.
| proportion of participants | CT-P6 | Herceptin |
|---|---|---|
| 1 year | 0.95 (0.91 to 0.97) | 0.96 (0.93 to 0.98) |
| 2 years | 0.87 (0.81 to 0.90) | 0.89 (0.85 to 0.92) |
| 3 years | 0.82 (0.77 to 0.87) | 0.82 (0.75 to 0.88) |
Progression-free survival was defined as the interval between randomization and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.
| proportion of participants | CT-P6 | Herceptin |
|---|---|---|
| 1 year | 0.99 (0.97 to 1.00) | 0.98 (0.95 to 0.99) |
| 2 years | 0.90 (0.86 to 0.94) | 0.93 (0.89 to 0.95) |
| 3 years | 0.82 (0.77 to 0.87) | 0.87 (0.82 to 0.90) |
Overall survival was defined as the interval between randomization and death from any cause.
| proportion of participants | CT-P6 | Herceptin |
|---|---|---|
| 1 year | 1.00 (1.00 to 1.00) | 1.00 (0.97 to 1.00) |
| 2 years | 0.98 (0.95 to 0.99) | 0.98 (0.96 to 0.99) |
| 3 years | 0.95 (0.91 to 0.97) | 0.94 (0.90 to 0.96) |
If recurrence or progression of disease occurred at any time during the study, the progressed tumor site was recorded in the "recurrence or progression of disease" eCRF page as local, regional, or distant, with diagnostic method and whether positive cytology or histology or not. The resulting recurrence or progression of disease information was summarized as secondary endpoint.
| participants | CT-P6 | Herceptin |
|---|---|---|
| Overall Period | 41 | 35 |
| Neoadjuvant Period | 1 | 2 |
| Adjuvant Period | 5 | 3 |
| Follow-up Period | 35 | 30 |
Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.
| µg/mL | CT-P6 | Herceptin |
|---|---|---|
| Cycle 1 | 186.428 ± 69.0828 | 178.567 ± 55.3800 |
| Cycle 2 | 145.078 ± 47.7899 | 138.989 ± 45.7103 |
| Cycle 3 | 145.183 ± 44.5392 | 141.130 ± 43.8189 |
| Cycle 4 | 148.541 ± 54.2737 | 137.465 ± 45.6914 |
| Cycle 5 | 136.210 ± 44.6078 | 135.307 ± 47.1950 |
| Cycle 6 | 143.569 ± 42.4510 | 143.605 ± 51.2868 |
| Cycle 7 | 146.726 ± 48.0249 | 141.468 ± 43.1823 |
| Cycle 8 | 145.081 ± 41.5382 | 144.238 ± 57.3618 |
Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.
| µg/mL | CT-P6 | Herceptin |
|---|---|---|
| Cycle 1 | 18.915 ± 22.9964 | 18.905 ± 21.2967 |
| Cycle 2 | 17.346 ± 17.9771 | 16.773 ± 16.8134 |
| Cycle 3 | 16.796 ± 17.2409 | 17.816 ± 23.3438 |
| Cycle 4 | 17.851 ± 20.1572 | 15.904 ± 15.8754 |
| Cycle 5 | 18.403 ± 19.9042 | 17.962 ± 17.9429 |
| Cycle 6 | 18.902 ± 20.2198 | 18.256 ± 17.6964 |
| Cycle 7 | 18.540 ± 14.3313 | 18.718 ± 18.5976 |
| Cycle 8 | 17.901 ± 7.2203 | 17.129 ± 10.0491 |
Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.
| percentage of responders | CT-P6 | Herceptin |
|---|---|---|
| The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes Regardless of DCIS | 51.61 (45.20 to 57.98) | 55.08 (48.76 to 61.28) |
Collected over Adverse events were assessed from the date the informed consent form is signed until up to 30 days from last dose of study drug, regardless of the relationship to the study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CT-P6 | — | 22/271 (8.1%) | 263/271 (97%) |
| Herceptin | — | 36/278 (12.9%) | 264/278 (95%) |
| Event | CT-P6 | Herceptin |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/271 | 3/278 |
| AnemiaBlood and lymphatic system disorders | 1/271 | 3/278 |
| NeutropeniaBlood and lymphatic system disorders | 2/271 | 3/278 |
| PneumoniaInfections and infestations | 2/271 | 1/278 |
| Device related infectionInfections and infestations | 0/271 | 2/278 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/271 | 2/278 |
| Adams-Stokes syndromeCardiac disorders | 1/271 | 0/278 |
| Abdominal painGastrointestinal disorders | 1/271 | 0/278 |
| Pancreatitis acuteGastrointestinal disorders | 1/271 | 0/278 |
| StomatitisGastrointestinal disorders | 1/271 | 0/278 |
| Event | CT-P6 | Herceptin |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 196/271 | 213/278 |
| NeutropeniaBlood and lymphatic system disorders | 95/271 | 116/278 |
| NauseaGastrointestinal disorders | 99/271 | 94/278 |
| AnaemiaBlood and lymphatic system disorders | 59/271 | 67/278 |
| FatigueGeneral disorders | 53/271 | 62/278 |
| DiarrhoeaGastrointestinal disorders | 52/271 | 50/278 |
| AstheniaGeneral disorders | 47/271 | 38/278 |
| StomatitisGastrointestinal disorders | 46/271 | 33/278 |
| LeukopeniaBlood and lymphatic system disorders | 28/271 | 41/278 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/271 | 40/278 |
| Age, Continuous(years) | CT-P6 | Herceptin | Total |
|---|---|---|---|
| Median | 53.0 (24 to 79) | 52.5 (22 to 74) | 53.0 (22 to 79) |
| Sex: Female, Male(Participants) | CT-P6 | Herceptin | Total |
|---|---|---|---|
| Female | 278 | 284 | 562 |
| Male | 0 | 0 | 0 |
Ran from Jun 2014 to primary completion in May 2016, 23 months.
Results were first posted in Oct 2019, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab